Press Release: Novartis: Sandoz Application for proposed biosimilar adalimumab''s high concentration formulation accepted by EMA
-- Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study -- Adalimumab''s high-concentration 100 mg|mL formulation aims to provide an enhanced yet familiar experience for patients -- Submission builds on Sandoz'' well established biosimilar…
Press Release: Novartis: Sandoz Application for proposed biosimilar adalimumab''s high concentration formulation accepted by EMA
-- Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study -- Adalimumab''s high-concentration 100 mg|mL formulation aims to provide an enhanced yet familiar experience for patients -- Submission builds on Sandoz'' well established biosimilar…